Pipettes in a row

Discovering scientific breakthroughs and developing novel therapies for complex, debilitating diseases has always been our focus

  1. Home
  2. Products & Research
  3. Research Pipeline

With many potential new therapies currently in clinical trials, our ambition is to be the industry leader in specialty care.

Explore highlights of our research and development pipeline across our four areas of focus.

Items marked with ^ are being developed in collaboration with Regeneron, with * are being developed in collaboration with Alnylam®, and with ♦ are being developed in collaboration with Principia Biopharma Inc. Items shown with a † denote a Phase 2/3 trial.

Product Candidate Technology Phase I Phase II Phase III Current Phase

Immunology

Dupilumab^
Asthma
mAb Dupilumab^ Asthma - Phase I - 100% of progress Dupilumab^ Asthma - Phase II - 100% of progress Dupilumab^ Asthma - Phase III - 75% of progress PHASE III
Dupilumab^
Nasal Polyposis
mAb Dupilumab^ Nasal Polyposis - Phase I - 100% of progress Dupilumab^ Nasal Polyposis - Phase II - 100% of progress Dupilumab^ Nasal Polyposis - Phase III - 25% of progress PHASE III
Dupilumab^
Eosinophilic esophagitis
mAb Dupilumab^ Eosinophilic esophagitis - Phase I - 100% of progress Dupilumab^ Eosinophilic esophagitis - Phase II - 25% of progress Dupilumab^ Eosinophilic esophagitis - Phase III - 0% of progress PHASE II
SAR100842
Systemic Sclerosis
mAb SAR100842 Systemic Sclerosis - Phase I - 100% of progress SAR100842 Systemic Sclerosis - Phase II - 25% of progress SAR100842 Systemic Sclerosis - Phase III - 0% of progress PHASE II
SAR156597
Systemic Scleroderma
mAb SAR156597 Systemic Scleroderma - Phase I - 100% of progress SAR156597 Systemic Scleroderma - Phase II - 25% of progress SAR156597 Systemic Scleroderma - Phase III - 0% of progress PHASE II
SAR439794
Peanut Allergy
mAb SAR439794 Peanut Allergy - Phase I - 50% of progress SAR439794 Peanut Allergy - Phase II - 0% of progress SAR439794 Peanut Allergy - Phase III - 0% of progress PHASE I
SAR440340
Asthma & COPD
mAb SAR440340 Asthma & COPD - Phase I - 50% of progress SAR440340 Asthma & COPD - Phase II - 0% of progress SAR440340 Asthma & COPD - Phase III - 0% of progress PHASE I

Oncology

Isatuximab
Relapsed Refractory Multiple Myeloma
mAb Isatuximab Relapsed Refractory Multiple Myeloma - Phase I - 100% of progress Isatuximab Relapsed Refractory Multiple Myeloma - Phase II - 100% of progress Isatuximab Relapsed Refractory Multiple Myeloma - Phase III - 25% of progress PHASE III
Cemiplimab^
1st Line Non-small Cell Lung Cancer
mAb Cemiplimab^ 1st Line Non-small Cell Lung Cancer - Phase I - 100% of progress Cemiplimab^ 1st Line Non-small Cell Lung Cancer - Phase II - 100% of progress Cemiplimab^ 1st Line Non-small Cell Lung Cancer - Phase III - 25% of progress PHASE III
Cemiplimab^
Cutaneous Squamous Cell Carcinoma
mAb Cemiplimab^ Cutaneous Squamous Cell Carcinoma - Phase I - 100% of progress Cemiplimab^ Cutaneous Squamous Cell Carcinoma - Phase II - 100% of progress Cemiplimab^ Cutaneous Squamous Cell Carcinoma - Phase III - 0% of progress PHASE II
Isatuximab
Acute Lymphoblastic Leukemia
mAb Isatuximab Acute Lymphoblastic Leukemia - Phase I - 100% of progress Isatuximab Acute Lymphoblastic Leukemia - Phase II - 50% of progress Isatuximab Acute Lymphoblastic Leukemia - Phase III - 0% of progress PHASE II
Cemiplimab^
Advanced BCC
mAb Cemiplimab^ Advanced BCC - Phase I - 100% of progress Cemiplimab^ Advanced BCC - Phase II - 50% of progress Cemiplimab^ Advanced BCC - Phase III - 0% of progress PHASE II
SAR566658
Solid tumors
mAb SAR566658 Solid tumors - Phase I - 100% of progress SAR566658 Solid tumors - Phase II - 50% of progress SAR566658 Solid tumors - Phase III - 0% of progress PHASE II
Cemiplimab^
Head & Neck Cancer
mAb Cemiplimab^ Head & Neck Cancer - Phase I - 50% of progress Cemiplimab^ Head & Neck Cancer - Phase II - 0% of progress Cemiplimab^ Head & Neck Cancer - Phase III - 0% of progress PHASE I
SAR439459
Metastatic Melanoma
mAb SAR439459 Metastatic Melanoma - Phase I - 50% of progress SAR439459 Metastatic Melanoma - Phase II - 0% of progress SAR439459 Metastatic Melanoma - Phase III - 0% of progress PHASE I
SAR408701
Solid tumors
mAb SAR408701 Solid tumors - Phase I - 50% of progress SAR408701 Solid tumors - Phase II - 0% of progress SAR408701 Solid tumors - Phase III - 0% of progress PHASE I
SAR428926
Solid tumors
mAb SAR428926 Solid tumors - Phase I - 50% of progress SAR428926 Solid tumors - Phase II - 0% of progress SAR428926 Solid tumors - Phase III - 0% of progress PHASE I

Rare Diseases

Patisiran*
hATTR Amyloidosis
RNAi Patisiran* hATTR Amyloidosis - Phase I - 100% of progress Patisiran* hATTR Amyloidosis - Phase II - 100% of progress Patisiran* hATTR Amyloidosis - Phase III - 100% of progress PHASE III
Fitusiran*
Hemophilia
RNAi Fitusiran* Hemophilia - Phase I - 100% of progress Fitusiran* Hemophilia - Phase II - 100% of progress Fitusiran* Hemophilia - Phase III - 50% of progress PHASE III
NeoGAA
Pompe disease, 2nd generation enzyme
protein-based therapy NeoGAA Pompe disease, 2nd generation enzyme - Phase I - 100% of progress NeoGAA Pompe disease, 2nd generation enzyme - Phase II - 100% of progress NeoGAA Pompe disease, 2nd generation enzyme - Phase III - 25% of progress PHASE III
Olipudase Alfa†
Acid Sphingomyelinase Deficiency (ASMD)
protein-based therapy Olipudase Alfa† Acid Sphingomyelinase Deficiency (ASMD) - Phase I - 100% of progress Olipudase Alfa† Acid Sphingomyelinase Deficiency (ASMD) - Phase II - 100% of progress Olipudase Alfa† Acid Sphingomyelinase Deficiency (ASMD) - Phase III - 0% of progress PHASE II
Venglustat
Fabry disease
small molecule venglustat Fabry disease - Phase I - 100% of progress venglustat Fabry disease - Phase II - 100% of progress venglustat Fabry disease - Phase III - 0% of progress PHASE II
Venglustat
Parkinson's disease with a GBA mutation
small molecule venglustat Parkinson's disease with a GBA mutation - Phase I - 100% of progress venglustat Parkinson's disease with a GBA mutation - Phase II - 25% of progress venglustat Parkinson's disease with a GBA mutation - Phase III - 0% of progress PHASE II
Venglustat
Gaucher Type 3
small molecule venglustat Gaucher Type 3 - Phase I - 100% of progress venglustat Gaucher Type 3 - Phase II - 25% of progress venglustat Gaucher Type 3 - Phase III - 0% of progress PHASE II

Multiple Sclerosis

PRN2246♦
Multiple Sclerosis
BTK inhibitor GLD52 (GZ402668) Multiple Sclerosis - Phase I - 25% of progress GLD52 (GZ402668) Multiple Sclerosis - Phase II - 0% of progress GLD52 (GZ402668) Solid tumors - Phase III - 0% of progress PHASE I


The agents mentioned here are investigational and have not been approved by the US Food and Drug Administration (FDA) or any other regulatory agency worldwide for the uses under investigation.

In addition to the candidates in clinical development, we are conducting earlier stage research in a range of therapeutic areas including genetic diseases such as cystic fibrosis, spinal muscular atrophy, and Lebers congenital amaurosis type 1. We have several programs in multiple sclerosis with molecules addressing areas of unmet need, using approaches such as immunomodulation, neuroprotection, and remylination.

Scientist in lab

NeoGAA clinical trial

Learn more about the ongoing phase 3 clinical trial for NeoGAA, an investigational enzyme replacement therapy being studied for the treatment of Pompe disease.
Scientist at microscope

Sanofi’s R&D portfolio

The full Sanofi research pipeline focuses on finding innovative solutions to a variety of major public health challenges.
GO
SAUS.GZ.17.11.8985
Last update: 1/2018